Toggle Offcanvas
...
 
Denosumab Tenders

Denosumab Tenders

View Denosumab tenders, RFPs and contracts. Bid on readily available Denosumab tenders with the best and most comprehensive tendering platform, since 2002.
Denosumab is a monoclonal antibody used to treat osteoporosis and bone loss in cancer patients. It blocks a protein called RANKL, reducing bone breakdown and strengthening bones.

Bidding for Denosumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Denosumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Denosumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Denosumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

40 Live Notices for Denosumab Tenders

Showing 1 to 20

Denosumab Supply Agreement Injectable Solution In Case Of Non -Office Of Cenabast For The Salvador Hospital
country Chile
posting date30 May 2025
deadline18 Jun 2025
Judicial Acquisition Of Medicines: Denosumab
country Brazil
posting date29 May 2025
deadline13 Jun 2025
Judicial Acquisition Of Medicines: Denosumab.
country Brazil
posting date29 May 2025
deadline13 Jun 2025
Judicial Acquisition Of Medicines: Denosumab.
country Brazil
posting date29 May 2025
deadline13 Jun 2025
Drug Acquisition, By Exemption From Bidding, For The Purpose Of Complying With Judicial Decisions Given, In The Face Of The State Of Rio Grande Do Norte: Denosumab 60Mg/Ml Injectable Solution; Denosumab 70Mg/Ml Injectable Solution; Iloprost 10Mcg/Ml Solution For Nebulization Box With 30 Ampoules. *
country Brazil
posting date27 May 2025
deadline04 Jun 2025
Judicial Acquisition Of Medicines: Denosumab.
country Brazil
posting date26 May 2025
deadline10 Jun 2025
Completion Of Non-Exclusive Discount Agreements According To §130A (8) Sgb V On Various Active Ingredient/En/Combinations With Any Final Option Within The Framework Of The So-Called Open House Procedure
country Germany
posting date27 May 2025
deadline05 Jun 2027
Judicial Acquisition Of Medicines: Denosumab
country Brazil
posting date22 May 2025
deadline06 Jun 2025
Object: Electronic Auction - Acquisition Medicines To Meet The Curitiba Health Group (Gsau -Ct)
country Brazil
posting date22 May 2025
deadline06 Jun 2025
Delivery Of Medicinal Products
country Poland
posting date21 May 2025
deadline05 Jun 2025
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Denosumab, Atc M05Bx04 For The Time 01.07.2025 - 30.06.2026 (Plus Extension Option 1X 12 Months)
country Germany
posting date20 May 2025
deadline05 May 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Denosumab, Atc M05Bx04 For The Time 01.07.2025 - 30.06.2026 (Plus Extension Option 1X 12 Months)
country Germany
posting date20 May 2025
deadline05 May 2027
Open House Pharmaceutical Discounts On The Active Ingredient Denosumab, Trade Name Prolia, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027
Medicines With The Active Ingredient Denosumab (Atc: M05Bx04)
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Dact Treaties For The Active Ingredient Denosumab, Trade Name Xgeva, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027
Medicines With The Active Ingredient Denosumab (Atc: M05Bx04)
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discount Contracts For The Active Ingredient Denosumab, Trade Name Xgeva, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Denosumab, Trade Name Prolia, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Dact Treaties For The Active Ingredient Denosumab, Trade Name Xgeva, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Denosumab, Trade Name Prolia, Atc M05Bx04
country Germany
posting date19 May 2025
deadline30 Apr 2027

Share Share this page